About B-MoGen
B-MoGen is a company based in Minneapolis (United States) founded in 2015 was acquired by Bio-Techne in June 2019. B-MoGen has raised $1.03 million across 5 funding rounds from investors including Bio-Techne and HHS. B-MoGen offers products and services including TcBuster, Recombinant Proteins, Antibodies, ELISAs, and Luminex Assays. B-MoGen operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Korro Bio, among others.
- Headquarter Minneapolis, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name R&D Systems, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$1.03 M (USD)
in 5 rounds
-
Latest Funding Round
$188.54 K (USD), Grant
Aug 15, 2018
-
Investors
Bio-Techne
& 1 more
-
Employee Count
Not available
-
Acquired by
Bio-Techne
(Jun 04, 2019)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of B-MoGen
B-MoGen offers a comprehensive portfolio of products and services, including TcBuster, Recombinant Proteins, Antibodies, ELISAs, and Luminex Assays.
Non-viral system for stable gene transfer in cell therapies
Proteins for biological assays and cell culture applications
Used in ELISAs and immunoassays for protein detection
Kits for measuring proteins in research and diagnostics
Platforms for simultaneous biomarker analysis in workflows
Funding Insights of B-MoGen
B-MoGen has successfully raised a total of $1.03M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $188.54 thousand completed in August 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in B-MoGen
B-MoGen has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Bio-Techne and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked | |
|
Developer of biotech reagents, instruments and clinical diagnostic products
|
Locked | Locked | Locked |
Investor details for B-MoGen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by B-MoGen
Investment portfolio details for B-MoGen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - B-MoGen
Detailed financials for B-MoGen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
B-Mogen Comparisons
Peer comparison for B-MoGen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of B-MoGen
B-MoGen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Korro Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
RNA-editing technologies are provided for precision medicine applications.
|
|
| Locked | Locked | Locked |
Dental implants and regenerative dentistry products are developed.
|
Detailed competitors of B-MoGen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on B-Mogen
Complete news archive for B-MoGen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about B-MoGen
B-MoGen was founded in 2015 and raised its 1st funding round 1 year after it was founded.
B-MoGen is headquartered in Minneapolis, United States. It is registered at Minneapolis, Minnesota, United States.
B-MoGen is a funded company, having raised a total of $1.03M across 5 funding rounds to date.
B-MoGen was founded in 2015 in Minneapolis, United States, within the biotechnology sector focused on genetic technologies. The Sleeping Beauty transposon system is utilized to create solutions that facilitate gene delivery in challenging cell types, such as primary cells. Enhancements to gene expression duration are provided, alongside services for custom vector production and targeted genome modifications. Operations emphasize practical applications in research and therapeutic development.
B-MoGen's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
B-MoGen offers TcBuster, Recombinant Proteins, Antibodies, ELISAs, and Luminex Assays.
B-MoGen has 2 investors. Key investors include Bio-Techne, and HHS.